Interested in learning all the hard data behind the article
Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
References 1 Martinez-ReyesIChandelNS
While the number of particles in the second reconstruction was much lower than the first, the data were consistent with a lower number of particles in a CT-like conformation (~ 17% of particles) relative to the bypass conformation (55% of particles) compared to the percentage of particles previously observed for the Amy-CTR-Gs complex (note, in the repeat experiment 28% of the particles could not be confidently classified, due to poorly resolved in ECD features) (Supplementary Fig
Always inform your provider directly about your medication to avoid confusion
Its active ingredient, Semaglutide base, helps reduce appetite, slows digestion, and improves the body's response to rising blood sugar levels